In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANALYSIS: Tax reforms would boost R&D by $20bn, add 600k+ jobs

This article was originally published in Scrip

Executive Summary

A new analysis from Ernst & Young has provided American biotechs and other small research-intensive businesses the evidence they need to back up their pleas to Congress to change certain tax rules for "pre-revenue" innovators, with the report showing adoption of three proposals could increase total investment in those companies by $20.6bn and result in the creation of about 623,000 new jobs.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC022283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel